on Protagonist Therapeutics, Inc. (NASDAQ:PTGX)
Protagonist Therapeutics Introduces PN-477 for Obesity Treatment
Protagonist Therapeutics has announced the nomination of its new development candidate, PN-477, aimed at treating obesity. PN-477 is a triple agonist peptide that targets GLP-1, GIP, and GCG receptors, available in both oral (PN-477o) and injectable (PN-477sc) forms. The company emphasizes the potential of PN-477 to balance body weight reduction with improved tolerability and effectiveness.
The triple agonist has undergone comprehensive preclinical evaluations, demonstrating promise in models of obesity and glycemic control. Phase I clinical studies for PN-477 are slated to begin in the second quarter of 2026. Protagonist anticipates that a combination of oral and injectable forms will provide a competitive edge in obesity treatment options.
Dr. Dinesh V. Patel, CEO of Protagonist, highlighted the potential of PN-477 as a groundbreaking therapeutic option, bridging the gap between existing treatments and enhancing efficacy with its unique triple activation mechanism.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Protagonist Therapeutics, Inc. news